PubMed · 4160955
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
C P Aber, P E Brunt, E W Jones, T G Richards, A H Short. 1966-06-25. Liver function after myocardial infarction.. https://doi.org/10.1016/s0140-6736(66)90301-1
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
The rapid urease test is a simple, sensitive, and highly specific test that enables the endoscopist to diagnose Helicobacter pylori infection in the endoscopy room. Determination of the infection status of Helicobacter pylori by biopsies from the gastric body had a significantly higher sensitivity than antral biopsies. A false-negative reaction by rapid urease test occurred the use of antibiotics (correlates with clearance of the bacteria) and the use of proton pump inhibitor or a part of mucosal protective agents(correlates urease inhibitory effect) and in the case of non-urease producing Helicobacter pylori. The rapid urease test satisfactory overall sensitivity before eradication treatment. However, the sensitivity of these rapid urease tests was lower after eradication than before eradication.
In Japan, The new triple therapy was opened for Helicobacter pylori (HP) eradication from Nov. 1, 2000. The Japanese Society for Helicobacter Research presented a guideline for HP eradication. It recommended that HP infection should be checked at least 4 weeks after the treatment for peptic ulcer and HP infection using HPIgG antibody, rapid urease test, urea breath test, histology and/or culture. However, it did not state the best way and suitable timing to check HP infection after the eradication therapy. In this study, we investigated the accuracy of PyloriTek test(a 1-h rapid urease test) and tried to establish the suitable timing for checking HP infection after eradication therapy. In conclusion, when patients are examined more than 4 months after eradication therapy, the use of PyloriTek alone may be sufficient for correctly diagnosing HP infection.
UNLABELLED: Glucose 6-phosphate dehydrogenase (G-6-PD) deficiency is common in the Thai population and is the cause of neonatal hyperbilirubinemia and hemolytic anemia. This X-linked disorder is much more common in males than females. The objectives of this study were to compare the result of the screening methemoglobin reduction test (MRT) with the gold standard G-6-PD activity, and also to determine the prevalence of G-6-PD deficiency in the cord blood and blood of neonates with hyperbilirubinemia. Five hunderd and twenty two randomly selected cord blood (350 males, 172 females) and 229 peripheral blood from neonates with hyperbilirubinemia were assayed for G-6-PD enzyme activity using a WHO-recommended standard test as well as methemoglobin reduction (MR) test. The results showed that prevalence of G-6-PD deficiency from the cord blood was 11.1 per cent in males, and 5.59 per cent in females. Among newborns with neonatal jaundice, the prevalence of G-6-PD deficiency was 22.1 per cent in males and 10.1 per cent in females. MRT in cord blood G-6-PD deficiency screening had acceptable sensitivity (85.7%) and high specificity (98.1%). The sensitivity of MRT in jaundiced infants was low (60.0%) whereas the specificity was acceptable (92.1%). The negative predictive values were more than 90 per cent while the positive predictive values were low (61-65%) from both specimens. CONCLUSIONS: G-6-PD deficiency is common in the Thai population, both in males and females and can be screened from cord blood by using low cost MRT. G-6-PD deficiency contributes to 20 per cent of neonatal jaundice, and screening with MRT yields low sensitivity.